Prime Medicine, Inc. (PRME)
(Delayed Data from NSDQ)
$4.28 USD
-0.03 (-0.70%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $4.28 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
PRME 4.28 -0.03(-0.70%)
Will PRME be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PRME based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PRME
Prime Medicine (PRME) Stock: Buy or Sell Before Q2 Earnings?
Prime Medicine (PRME) Gains 16.4% in 3 Months: Buy Now or Wait?
PRME: What are Zacks experts saying now?
Zacks Private Portfolio Services
Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio
Wall Street Analysts Believe Prime Medicine, Inc. (PRME) Could Rally 120.95%: Here's is How to Trade
Does Prime Medicine, Inc. (PRME) Have the Potential to Rally 133.64% as Wall Street Analysts Expect?
Other News for PRME
Prime Medicine to Participate in Upcoming Investor Conferences
Prime Drink Group Corp. Enters Into a Final Share Purchase Agreement to Acquire Triani Canada Inc.
Prime Drink Group Finalizes Triani Acquisition Deal
Analysts Offer Insights on Healthcare Companies: Guardant Health (GH) and Prime Medicine, Inc. (PRME)
Buy Rating for Prime Medicine, Inc. on Strong Pipeline and Financial Health